Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BBIO Stock News and Mentions of BridgeBio Pharma, Inc. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where BridgeBio Pharma Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of BridgeBio Pharma, Inc. (BBIO).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the BridgeBio Pharma stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of BridgeBio Pharma, Inc. (BBIO)
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Will BridgeBio Pharma ( BBIO ) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 10, 2024 (11:30) / "GlobeNewswire" (by Inc.)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
PALO ALTO, Calif., April 10, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the compensation committee of ...
In Article Trend: Somewhat-Bullish
April 7, 2024 (17:15) / "GlobeNewswire" (by BridgeBio Pharma)
BridgeBio Pharma Presents Cardiac Magnetic Resonance ( CMR ) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy ( ATTR-CM )
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression ...
In Article Trend: Neutral
March 20, 2024 (11:30) / "GlobeNewswire" (by BridgeBio Pharma)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
PALO ALTO, Calif., March 20, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 16, 2024, the compensation committee of ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:30) / "Benzinga" (by Globe Newswire)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., March 20, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
In Article Trend: Somewhat-Bullish
March 6, 2024 (04:53) / "GlobeNewswire" (by Inc.)
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif., March 05, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 ...
In Article Trend: Neutral
March 5, 2024 (13:00) / "Benzinga" (by Globe Newswire)
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO )
BOSTON and PLEASANTON, Calif., March 05, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc.
In Article Trend: Neutral
March 5, 2024 (13:00) / "Benzinga" (by Globe Newswire)
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO )
BOSTON and PLEASANTON, Calif., March 05, 2024 ( GLOBE NEWSWIRE ) -- Akari Therapeutics, Plc AKTX, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc.
In Article Trend: Neutral
March 4, 2024 (21:17) / "Benzinga" (by Globe Newswire)
BridgeBio Pharma Announces Proposed Public Offering of Common Stock - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., March 04, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. BBIO ( "BridgeBio" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common ...
In Article Trend: Neutral
March 4, 2024 (21:17) / "GlobeNewswire" (by BridgeBio Pharma)
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., March 04, 2024 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" ) , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares ...
In Article Trend: Neutral
March 4, 2024 (17:31) / "Benzinga" (by Vandana Singh)
What's Going On With BridgeBio Pharma Stock On Monday? - BridgeBio Pharma ( NASDAQ:BBIO )
Monday, BridgeBio Pharma Inc BBIO and Bayer AG BAYRY BAYZF announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million, including upfront and near-term milestone payments and ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (07:30) / "GlobeNewswire" (by BridgeBio Pharma)
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy ( ATTR-CM ) in Europe ...
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
IMAC Holdings, Inc. (IMAC)
Tilray, Inc. (TLRY)
Zoetis Inc. (ZTS)
Pasithea Therapeutics Corp. (KTTA)
Galera Therapeutics, Inc. (GRTX)
OrganiGram Holdings Inc. (OGI)
Aeterna Zentaris Inc. (AEZS)
Aurora Cannabis Inc. (ACB)
China Evergrande New Energy Vehicle Group Lim. (EVGRF)
Kura Oncology, Inc. (KURA)
This website uses cookies to ensure you get the best experience on our website